NeoGenomics, Inc.
$8.23
▲
3.23%
2026-04-21 08:22:01
www.neogenomics.com
NCM: NEO
Explore NeoGenomics, Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$1.06 B
Current Price
$8.23
52W High / Low
$13.74 / $4.72
Stock P/E
—
Book Value
$6.49
Dividend Yield
—
ROCE
-6.93%
ROE
-12.43%
Face Value
—
EPS
$-0.84
Exp Qtr EPS
—
Sector
Healthcare
Industry
Diagnostics & Research
Employees
2,500
Beta
1.71
Debt / Equity
48.95
Current Ratio
4.26
Quick Ratio
3.94
Forward P/E
24.1
Price / Sales
1.38
Enterprise Value
$1.25 B
EV / EBITDA
-685.39
EV / Revenue
1.72
Rating
None
Target Price
$14.81
EPS Forecast (FY)
—
Pros
- Balance sheet leverage appears manageable.
- Short-term liquidity looks comfortable.
Cons
- Return on equity is on the weaker side.
- Capital efficiency is modest.
- Operating margin is thin.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | Mainz Biomed N.V. | $0.47 | — | $5.89 M | — | -252.7% | -4.88% | $4.43 / $0.4 | $0.62 |
| 2. | Precipio, Inc. | $28.15 | — | $50.21 M | — | -6.84% | -2.72% | $29.8 / $5.19 | $8.18 |
| 3. | Medpace Holdings, Inc. | $513.23 | 33.75 | $14.67 B | — | 84.68% | 70.23% | $628.92 / $250.05 | $16.18 |
| 4. | IDEXX Laboratories, Inc. | $580.27 | 44.49 | $46.26 B | — | 61.76% | 66.2% | $769.98 / $402.85 | $20.14 |
| 5. | Sotera Health Company | $16.28 | 59.4 | $4.63 B | — | 12.01% | 15.42% | $19.85 / $10.17 | $2.13 |
| 6. | Personalis, Inc. | $6.34 | — | $663.37 M | — | -29.9% | -35.02% | $11.5 / $3.09 | $2.55 |
| 7. | Twist Bioscience Corporation | $61.88 | — | $3.79 B | — | -24.75% | -16.79% | $62.09 / $23.3 | $7.44 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | |
|---|---|---|---|---|---|
| Sales | 190.17 M | 187.8 M | 181.33 M | 168.03 M | 172 M |
| Operating Profit | -12.79 M | -19.93 M | -27.59 M | -27.82 M | -16.69 M |
| Net Profit | -9.88 M | -27.13 M | -45.09 M | -25.92 M | -15.32 M |
| EPS in Rs | -0.08 | -0.21 | -0.35 | -0.2 | -0.12 |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 727.33 M | 660.57 M | 591.64 M | 509.73 M |
| Operating Profit | -88.13 M | -85.45 M | -96.65 M | -153.11 M |
| Net Profit | -108.03 M | -78.73 M | -87.97 M | -144.25 M |
| EPS in Rs | -0.83 | -0.6 | -0.68 | -1.11 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 1.36 B | 1.64 B | 1.68 B | 1.74 B |
| Total Liabilities | 523.27 M | 735.7 M | 739.69 M | 742.01 M |
| Equity | 836.56 M | 902.34 M | 941.54 M | 998.02 M |
| Current Assets | 376.29 M | 596.02 M | 596.81 M | 605.29 M |
| Current Liabilities | 88.3 M | 301.24 M | 96.3 M | 89.93 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | 5.23 M | 7.02 M | -1.95 M | -65.99 M |
| Investing CF | -12.34 M | 12.86 M | 76.71 M | 0.52 M |
| Financing CF | -200.29 M | 4.65 M | 4.55 M | 11.83 M |
| Free CF | -21.78 M | -34.04 M | -30.7 M | -96.88 M |
| Capex | -27.01 M | -41.06 M | -28.75 M | -30.89 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Revenue Growth % | 11.65% | 16.07% | — | — |
| Earnings Growth % | 10.51% | 39.02% | — | — |
| Profit Margin % | -11.92% | -14.87% | -28.3% | — |
| Operating Margin % | -12.94% | -16.34% | -30.04% | — |
| Gross Margin % | 43.92% | 41.34% | 36.86% | — |
| EBITDA Margin % | -0.23% | -2.98% | -16.15% | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
No stock split history available.